As the presence of truncated PPM1D proteins leads to inactivation of the tumor suppressor p53, it is possible that PPM1D mutations generally associate with adverse outcomes in hematological diseases and other cancers where treatment-induced p53 function is required. This evidence concerns the gene PPM1D and hematologic disorder.